Garth Lees-Rolfe
Director of Finance/CFO at INHIBIKASE THERAPEUTICS, INC.
Net worth: - $ as of 2024-05-30
Profile
Garth Lees-Rolfe is currently the Chief Financial Officer at Inhibikase Therapeutics, Inc. He previously worked as the Vice President-Finance at F-star Therapeutics, Inc. Mr. Lees-Rolfe completed his undergraduate degree at Queensland University of Technology.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-04-14 | 0 ( -.--% ) | - $ | 2024-05-30 |
Garth Lees-Rolfe active positions
| Companies | Position | Start |
|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Director of Finance/CFO | 2024-03-30 |
Former positions of Garth Lees-Rolfe
| Companies | Position | End |
|---|---|---|
| F-STAR THERAPEUTICS, INC. | Corporate Officer/Principal | 2022-10-31 |
Training of Garth Lees-Rolfe
| Queensland University of Technology | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
F-star Therapeutics, Inc.
 F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Garth Lees-Rolfe
